Benchmarks for Interpretation of Score Differences on the SF-36 Health Survey for Patients with Diabetes  by Bjorner, Jakob B. et al.
Avai lable onl ine at www.sc iencedirect .comV A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 9 9 3 – 1 0 0 01098-3015/$36.00 –
Published by Elsevie
http://dx.doi.org/10.
E-mail: jbjorner@
* Address correspojournal homepage: www.elsevier .com/ locate / jva lBenchmarks for Interpretation of Score Differences on the SF-36 Health
Survey for Patients with Diabetes
Jakob B. Bjorner, MD, PhD1,2,*, Michael Lyng Wolden, MSc3, Jens Gundgaard, PhD3, Kate A. Miller, PhD1
1QualityMetric/OptumInsight, Lincoln, RI, USA; 2Department of Public Health, University of Copenhagen, Copenhagen, Denmark; 3Novo Nordisk A/S,
Copenhagen, Denmark
A B S T R A C TObjective: To estimate clinical and social benchmarks for inter
pretation of score differences on the Short-Form 36 Health Survey,
and apply these benchmarks to populations with diabetes
mellitus (DM). Methods: Using survival and logistic regression mod-
els, we reanalyzed data from three US cohorts: the Medical Outcomes
Study (N ¼ 3,445; 541 patients with DM), the Medicare Health Out-
comes Survey (N ¼ 78,183; 16,388 patients with DM), and the
QualityMetric 2009 Norming Study (N ¼ 4,040; 580 patients with
DM). Outcome variables were mortality, hospitalization, current
inability to work, and loss of ability to work. Results: Benchmarks
were robust across disease groups, but varied according to age and
score level. A 1-point lower score on the Physical Function, General
Health, and Physical Component Summary scales was associated
with a 1.05 to 1.09 relative risk (RR) of mortality for the typical
patient with DM, with stronger associations in the younger age
groups. For several scales (Physical Function, Role Physical, Bodilysee front matter Copyright & 2013, International S
r Inc.
1016/j.jval.2013.06.022
qualitymetric.com.
ndence to: Jakob B. Bjorner, QualityMetric/OptumIPain, General Health, Vitality, Social Function, and Role Emotional),
the associations with mortality also depended on score level, with
stronger associations in the lower score ranges (i.e., patients in
worse health). A 1-point lower score on the Physical Function, Role
Physical, Bodily Pain, General Health, Vitality, Social Function, and
Physical Component Summary scales implied a 1.02 to 1.04 RR of
hospitalization, a 1.07 to 1.12 RR of being unable to work, and a 1.04
to 1.07 RR of losing the ability to work. Conclusions: A 1-point lower
score on selected Short-Form 36 Health Survey scales is associated
with an excess risk of up to 9% for mortality and 12% for inability
to work.
Keywords: benchmarks, diabetes, interpretation, patient-reported
outcome, SF-36.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Assessing the health-related quality of life (HRQOL) of patients is
a critical element of care. For patients with diabetes mellitus
(DM), the physical burden, emotional consequences, and daily
self-care requirements [1] lead to large and well-documented
deﬁcits in HRQOL compared with the general population [2].
Low HRQOL may erode the capacity for self-care of patients
with diabetes, increasing their risk of complications and comorbi-
dities [1].
Both generic and disease-speciﬁc questionnaires can be used
to measure HRQOL among patients with DM [3,4]. The Short-
Form 36 Health Survey (SF-36) [5], the most common generic
HRQOL measure, has been validated for use in populations with
DM [3,6] and is widely used in DM research. Because HRQOL
measures are not usually part of routine clinical assessment,
clinicians may lack criteria for interpretation of score levels and
score differences.
This article aims to help users of the SF-36 answer the
following question: “I have found a score difference of X points.
Is this difference trivial, small, or large?” Our approach to thatquestion is to link SF-36 scores to four other outcomes whose
clinical signiﬁcance is intuitively clear: mortality, hospitalization,
inability to work, and loss of work. We label these outcomes as
benchmarks because they provide a standard by which to
evaluate the magnitude of a score difference. Thus, we would
consider a score difference to be large if it were associated with a
notable increase in, for example, mortality risk.
We associate differences in SF-36 scores with relative risks
(RRs) of the four outcomes. Building on prior work [5], we
hypothesize that each SF-36 scale is associated with each out-
come. We analyze the SF-36 scales as continuous variables and
report RRs for a 1-point score difference to allow easy calcula-
tions of RRs for other score differences. We present these bench-
marks as points of reference for interpreting what constitutes a
large or a small score difference even though the associations are
not necessarily causal.
While the present study is motivated by the need for inter-
pretation benchmarks within populations with diabetes, we
empirically test whether the interpretation depends on disease
or other characteristics. General interpretation guidelines across
diseases are standard for most physiological measures and haveociety for Pharmacoeconomics and Outcomes Research (ISPOR).
nsight, 24 Albion Road, Building 400, Lincoln, RI 02865, USA.
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across different disease areas. The issue, however, has not been
thoroughly tested for HRQOL measures.Methods
Data Sources
This analysis draws on three data sets (Table 1). The Medical
Outcomes Study (MOS) was an observational study of functional
status and well-being among 3445 chronically ill adult patientsTable 1 – Characteristics of data sources.
MOS
Total Diabe
Sample size 3,445 54
Study year (baseline) 1986
Outcomes
Deaths* (%) 7 13
Hospitalizations (%) 10 17
Unable to work (%) 25 32
Lost ability to work (%) 11 12
Demographics
Age (y), mean  SD 53  16 60 
o65 y (%) 72 62
6574 y (%) 19 31
74þ y (%) 8 7
Number of comorbidities, mean  SD
Of ﬁve conditions† 0.4  0.7 1.3 
Of all conditions‡ 1.7  1.9 2.8 
Education (%)
Less than high school 16 18
High school 30 34
Some college 27 27
College or more 27 21
Female (%) 62 56
Married (%) 59 64
SF-36 scores, mean§
PF 45.8 42.
RP 44.0 42.
BP 49.1 48.
GH 45.3 42.
VT 48.4 48.
SF 48.7 48.
RE 45.4 46.
MH 47.9 50.
PCS 46.1 42.
MCS 48.1 51.
BP, Bodily Pain; GH, General Health; MCS, Mental Component Summary;
Medical Outcomes Study; PCS, Physical Component Summary; PF, Physica
Limitations due to Physical Health; QM Norms, QualityMetric Patient-Rep
Form 36 Health Survey; VT, Vitality.
 MOS: 7-y mortality, MHOS: 2-y mortality.
† Five comorbidities were measured in all three data sets: angina, chroni
myocardial infarction.
‡ Total comorbidities were MOS, 9; MHOS, 11; and QM Norms, 21.
§ SDs of all SF-36 scores vary from 10.0 to 13.6
║ High scores in the diabetes group relative to total is likely due to
comparison group.with hypertension, non–insulin-dependent diabetes mellitus,
recent acute myocardial infarction, congestive heart failure, or
depressive disorder from Massachusetts, Illinois, and California
[7]. Patients were administered the paper and pencil version 1 of
the SF-36 (SF-36v1) in 1986, followed regularly for 4 years with
regards to health and well-being, and checked at 7 years regard-
ing mortality.
The Medicare Health Outcomes Survey (MHOS), which we
used for analysis of mortality, is a large, ongoing government-
funded study assessing the physical and mental health of
Medicare beneﬁciaries enrolled in managed care plans across
the United States [8]. Each MHOS cohort is prospectively followedStudy
MHOS QM Norms
tes Total Diabetes Total Diabetes
1 78,183 16,388 4,040 580
2005 2009
10 14 – –
– – – –
– – 8 17
– – – –
11 – – 51  17 59  14
6 9 74 59
44 46 19 29
49 46 8 12
0.6 0.7  1.0 1.8  1.0 0.3  0.6 1.3  0.7
1.8 2.3  1.9 3.6  2.0 2.6  2.5 5.0  2.8
29 34 8 12
38 37 30 37
33 30
31 29
30 22
58 53 51 44
54 54 52 54
5 39.3 35.4 48.3 40.9
5 42.4 39.2 48.7 42.6
2 45.3 42.5 49.3 43.6
6 45.0 40.9 47.7 41.8
2 48.4 45.3 49.7 46.2
7 46.4 43.3 49.3 45.7
8║ 46.3 43.8 49.5 46.4
6║ 49.9 47.8 50.0 48.5
3 40.8 37.0 48.1 40.4
1║ 50.9 48.9 50.2 49.4
MH, Mental Health; MHOS, Medicare Health Outcomes Survey; MOS,
l Functioning; RE, Role Limitations due to Emotional Health; RP, Role
orted Outcome Norming Survey; SF, Social Functioning; SF-36, Short-
c heart failure, chronic obstructive pulmonary disease, diabetes, and
the large proportion of patients with clinical depression in the
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 9 9 3 – 1 0 0 0 995for 2 years; the last cohort to complete the SF-36v1 (by paper and
pencil) was cohort 8 (n ¼ 78,183), which was selected in 2005.
The cross-sectional QualityMetric Patient-Reported Outcome
Norming Survey (QM Norms), which we used for analysis of
ability to work, administered version 2 of the SF-36 (SF-36v2) via
Internet to a nationally representative sample of 4040 adults in
the United States in 2009 [5]. The major difference between v1
and v2 of the SF-36 is an improvement in the response options for
the items concerning role limitations, reducing the ceiling prob-
lems of these scales [5]. The QM Norms study also includes self-
reported measures of morbidity, employment status, and health
resource use.
Variables
The studies recorded age, education, and marital status with
various degrees of detail (Table 1). We collapsed marital status
into married/not married to avoid small groups. Respondents in
all three studies also completed checklists of their current health
conditions: the MOS list included 9 conditions, the MHOS 12, and
the QM Norms 21. Included in all three checklists were diabetes,
angina, chronic heart failure, chronic obstructive pulmonary
disease, and myocardial infarction.
The SF-36 yields scores for eight scales: Physical Functioning
(PF), Role Limitations due to Physical Health (RP), Bodily Pain (BP),
General Health (GH), Vitality (VT), Social Functioning (SF), Role
Limitations due to Emotional Health (RE), and Mental Health
(MH). These scale scores can be combined to produce two
component summary scores: the Physical Component Summary
(PCS) and the Mental Component Summary (MCS). To aid inter-
pretation, norm-based scoring has been introduced for the SF-36
[5], setting the general population mean to 50 and the SD to 10 for
all scales. Scores typically range from 20 to 60, with higher scores
indicating better health [5].
In the MOS, mortality was assessed as date of death with
censoring 7 years after baseline, providing 20,400 person-years of
follow-up. In the MHOS, death was recorded as a dichotomous
variable at 2-year follow-up.
Hospitalization (overnight stay in hospital) was assessed in
the MOS through self-report at the 6-month follow-up.
Inability to work due to health was assessed at baseline in the
MOS and the QM Norms. MOS respondents who were neither
working (full or part time), retired, nor homemakers were asked
the question “Does your health keep you from working at a
paying job?” The QM Norms study asked all respondents, “Are
you now working at a paying job?” and we deﬁned inability to
work due to health by the response “No, because of my health.”
Lost ability to work 6 months after baseline was deﬁned in the
MOS as those who were not constrained from working because of
their health at baseline, but were so at the 6-month follow-up.
Statistical Modeling
We performed separate analyses for each combination of the SF-
36 scales and the four outcomes. The MOS mortality data were
analyzed by using a Cox proportional hazards model. Fit was
evaluated through the supremum test of the proportional haz-
ards assumption and through Martingale Residuals [9].
For the other outcomes (hospitalization, ability to work, and
loss of ability to work), we used logistic regression models
because they provided better ﬁt than Poisson regression models
[10] in terms of the Akaike Information Criterion [11]. We further
evaluated ﬁt of the logistic regression model through the
Hosmer-Lemeshow statistic [12].
All analyses included age, sex, education, marital status, and
medical conditions. We did not mutually control for other SF-36
scales. Because the same disease process often affects severalHRQOL outcomes, including several SF-36 scales would bias the
results to underestimate the strength of the association. We
evaluated models that used each medical diagnosis as an
independent variable, but found that a sum scale counting the
number of conditions provided better ﬁt according to the
Hosmer-Lemeshow statistic. We tested whether the association
between SF-36 scale scores and the outcomes depended on
diagnosis. This was done by deﬁning a class variable for type of
diagnosis (with “no diagnosis” as comparison category) and
testing the interaction between this variable and scale score. To
avoid the problem of classifying patients with multiple condi-
tions, these analyses were restricted to subsamples of respond-
ents with one or no diagnosis, termed the single disease
subsamples below. In the MHOS study, the variable deﬁned 12
diagnoses. In the MOS and QM Norms studies, we used three
categories (diabetes, other disease, and no diagnosis) to avoid
small groups.
In each analysis, the SF-36 scale or component summary
score was included as a continuous variable. We tested for
nonlinear effects by including quadratic and cubic terms in the
models. To avoid spurious nonlinear effects, all SF-36 scores were
recentered so that 50 were set to 0. We tested whether the
association between the SF-36 score and the outcome depended
on age, sex, education, marital status, or number of comorbidities
by including interaction terms between each background variable
and the score. In the MOS and QM Norms data, age was
recentered at age 50 years. Only signiﬁcant nonlinear terms and
interaction terms were kept in the ﬁnal model. Because of
multiple tests, we used a Bonferroni corrected alpha level,
correcting for the number of independent variables, interactions,
and nonlinear terms included in each analysis. The detailed
results can be found in Supplemental Materials found at http://
dx.doi.org/10.1016/j.jval.2013.06.022.
The scoring of PCS and MCS involves negative weights for
some scales: the PF, RP, and BP scales for the MCS and the RE and
MH scales for the PCS [13]. In particular, MCS scores of 58 or more
occur together with low PF and RP scores. Because this may cause
nonlinear results, we excluded cases with MCS scores of 58 or
more in all models that include the MCS as a predictor. This
criterion excluded 1% of the full sample and 2% of the diabetic
subsample in the MOS, 32% of the full sample and 34% of the
diabetic sample in the MHOS, and 23% of the full sample and 26%
of the diabetic sample in the QM Norms study.
Interpreting Results
To ease interpretation, parameters from the ﬁnal models were
transformed into RRs for a 1-point score difference—that is, the
RR of the outcome in question for a group that had a 1-point
lower score than the comparison group. For the proportional
hazards model, the log hazard is directly transformed into an RR.
In case of interactions or nonlinear effects, we calculated a range
of RRs to illustrate potential variability.
For the logistic regression model, we estimated the RR in the
following way: 1) we used the logistic regression model param-
eters to calculate the probability of the outcome for a given
combination of values for the SF-36 score and other covariates,
and 2) we then repeated the calculation for a score level 1 point
lower and calculated the RR as the ratio of the two probabilities. If
the outcome is common, the RR may not be constant even if the
model includes no interactions or nonlinear effects. Therefore,
we present a range of RRs from these analyses.
We calculated average RRs for patients with diabetes by using
the model parameters to calculate the linear predictor for each
patient with diabetes and taking the average across the diabetes
sample. We then repeated the calculation for a hypothetical
diabetes sample that had the same distribution of covariates,
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two linear predictors to calculate the average RRs for the diabetes
samples.Results
Mortality
In the MOS, the ﬁt tests suggested that scores for the PF, GH, VT,
and PCS should be modeled as time-dependent effects, assuming
one level of association for the ﬁrst 2 years after baseline and
another for years 3 through 7. Signiﬁcant associations between
score and mortality were found for the PF, RP, GH, VT, and SF
scales and for the PCS (P o 0.0025 for all tests). In the MHOS,
signiﬁcant associations were found for all scale and component
summary scores (P o 0.0001). In both the MOS and the MHOS
single disease subsamples, the associations between score and
mortality were robust across diseases and no test of interaction
between diagnosis and scale score was signiﬁcant. In theTable 2 – Estimated relative risk of mortality for a 1-poin
Study PF RP BP GH
MOS*
Variation by age
40 y 1.129† 1.021 NS 1.118†
50 y 1.099† 1.021 1.098†
60 y 1.071† 1.021 1.077†
70 y 1.043† 1.021 1.057†
80 y 1.015† 1.021 1.038†
MHOS‡
Variation by score level§
50 1.022 1.013 0.991 1.024
40 1.013 1.010 1.021 1.049
30 1.049 1.072 1.051 1.072
20 1.125 || 1.078 1.089
Variation by age§
o65 y 1.013 1.010 1.021 1.049
65–74 y 1.041 1.035 1.052 1.078
474 y 1.034 1.023 1.048 1.070
Variation by education§
oHS 1.003 0.996 1.012 1.036
HS 1.008 1.002 1.019 1.049
C 1.013 1.010 1.021 1.049
Variation by marital status§
Single 1.006 1.010 1.010 1.040
Married 1.013 1.010 1.021 1.049
Variation by number of comorbidities§
0 1.017 1.010 1.026 1.051
2 1.010 1.010 1.016 1.046
4 1.004 1.010 1.007 1.042
Model applied to subsample with diabetes
MOS* 1.090† 1.021 NS 1.091†
MHOS‡ 1.059 1.064 1.018 1.057
Note. Signiﬁcant interactions or nonlinear effects are denoted by italics.
BP, Bodily Pain; GH, General Health; MH, Mental Health; MHOS, Medicar
signiﬁcant; PF, Physical Functioning; RE, Role Limitations due to Emoti
Functioning; SF-36, Short-Form 36 Health Survey; VT, Vitality.
* Hazard rates based on proportional hazards model with 7-y mortality,
† Model included terms for time-varying risks. Hazard rates concern risk
‡ Relative risks calculated from a logistic regression model of 2-y mortal
§ Values not explicitly stated were chosen to represent the largest subgrou
o 65 y, male, college education (MHOS), college or more (MOS), marrie
|| Outside the score range for the scale.analyses described here, as well as in all subsequent analyses,
the ﬁnal model ﬁt was satisfactory, in that there was no statisti-
cally signiﬁcant misﬁt.
Table 2 presents the estimated RRs of mortality for a 1-point
lower SF-36 score. In the MOS, we found interaction effects with
age for the PF and GH scales and for the PCS. Associations were
much stronger in the younger age groups (RR 1.13– 1.14 for
persons 40 years old) than in the older age groups (RR 1.01–1.04
for persons 80 years old). In the MHOS study, signiﬁcant age
interactions were found for all scales and for the MCS (P o
0.0001), but not for the PCS. The age interaction effects were less
strong than in the MOS, with the largest RRs (up to 1.08) in the 65-
to 74-year-old group and smaller RRs in the younger and older
age groups. Also, in the MHOS, nonlinear effects of scale score
were found for all scales except the MH, implying that association
with mortality depended on score level and was strongest for low
score levels (RR 1.08–1.13, top row Fig. 1). In contrast, the MH scale
and both component summary scores show constant associa-
tions with mortality across the score range. The second row of
Figure 1 illustrates the absolute risk of 2-year mortality fort lower SF-36 score.
VT SF RE MH PCS MCS
1.063† 1.020 NS NS 1.137† NS
1.063† 1.020 1.104†
1.063† 1.020 1.073†
1.063† 1.020 1.042†
1.063† 1.020 1.013†
1.017 1.015 1.005 1.015 1.059 1.015
1.029 1.016 0.988 1.015 1.058 1.014
1.040 1.038 1.034 1.015 1.057 1.014
|| 1.079 || 1.015 1.055 1.014
1.029 1.027 0.988 1.015 1.058 1.014
1.059 1.059 1.015 1.040 1.057 1.048
1.053 1.054 1.008 1.036 1.053 1.043
1.028 1.007 0.988 1.015 1.058 1.014
1.028 1.015 0.988 1.015 1.058 1.014
1.029 1.016 0.988 1.015 1.058 1.014
1.028 1.008 0.979 1.008 1.049 1.002
1.029 1.016 0.988 1.015 1.058 1.014
1.031 1.019 0.991 1.017 1.058 1.017
1.026 1.013 0.985 1.013 1.058 1.012
1.022 1.006 0.980 1.009 1.058 1.006
1.063† 1.020 NS NS 1.094† NS
1.043 1.043 1.054 1.028 1.051 1.030
e Health Outcomes Survey; MOS, Medical Outcomes Study; NS, not
onal Health; RP, Role Limitations due to Physical Health; SF, Social
except where indicated.
s in the ﬁrst 2 y after baseline.
ity.
p of patients with diabetes in the samples: base score level ¼ 40, age
d, one comorbid condition.
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Fig. 1 – Graphs of selected risks of outcomes for different SF-36 score levels. SF-36, Short-Form 36 Health Survey.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 9 9 3 – 1 0 0 0 997different score levels (assuming age o 65 years, male, college
education, married, one diagnosis). For the GH scale, for example,
the risks are 2.4% for a score of 50 and 13.1% for a score of 20.
We also found interaction effects with number of comorbid-
ities for all scales except the RP and for the MCS. The largest RRs
were found for persons with few or no diagnoses. Finally, for
many scales we found weak interaction effects with education
and with marital status. Despite statistical signiﬁcance, these
interactions had only a minor impact on the RRs.
The bottom part of Table 2 depicts the average RRs estimated
for the subsamples with diabetes in the MOS and the MHOS.In the MOS data, a 1-point lower score on the PF, GH, and PCS was
associated with an RR of 1.09 for mortality. Associations for the
remaining scales were less strong. In the MHOS data, the largest
RR estimated for the subsample with diabetes was for the PF, RP,
and GH (RR 1.06).
Hospitalization
In the MOS, the PF, RP, BP, GH, VT, and SF scales and the PCS were
signiﬁcantly associated with the risk of hospitalization within 6
months (P o 0.005). We found neither nonlinear effects nor
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 9 9 3 – 1 0 0 0998interaction with any covariates. A 1-point lower score was
associated with increased risks of hospitalization ranging from
an RR of 1.02 to 1.04 (Table 3). In the single disease subsample,
the associations were robust across diagnoses.
Work Ability
In both the MOS and QM Norms data, all scales and the two
component summaries were signiﬁcantly associated with current
inability to work due to health (P o 0.0001). Quadratic effects
were found for the PF and SF scales in the MOS and for the PF
scale in the QM Norms study. The QM norms data showed
interactions for age (with PF, RP, and PCS), marital status (with
PF, RP, GH, VT, and MH), and number of comorbidities (GH and
RE). In the single disease subsamples, the associations between
score and work ability were robust across diseases.
In general, the strongest associations were seen for persons
in the high score range, for the young, for persons who wereTable 3 – Estimated relative risk of hospitalization, inab
lower SF-36 score.
Study/outcome PF RP BP GH
QM Norms/unable to work
Variation by score level*
50 1.206 1.159 1.112 1.1
40 1.152 1.155 1.109 1.1
30 1.097 1.141 1.103 1.1
20 1.049 1.101 1.087 1.1
Variation by age*
30 1.178 1.199 1.108 1.1
40 1.165 1.177 1.109 1.1
50 1.152 1.155 1.109 1.1
60 1.138 1.133 1.110 1.1
Variation by marital status*
Single 1.097 1.106 1.103 1.0
Married 1.152 1.155 1.109 1.1
Variation by number of comorbidities*
0 1.153 1.156 1.110 1.1
2 1.150 1.154 1.108 1.1
4 1.144 1.151 1.104 1.1
MOS/unable to work
Variation by score level*
50 1.147 1.064 1.083 1.1
40 1.088 1.105 1.074 1.1
30 1.041 1.120 1.059 1.0
20 1.014 † 1.039 1.0
MOS/loss of work ability
Variation by age*
30 1.055 1.057 1.043 0.9
40 1.055 1.056 1.042 1.0
50 1.054 1.055 1.042 1.0
60 1.053 1.055 1.041 1.0
Model applied to diabetic subsample
MOS/hospitalization 1.032 1.024 1.027 1.0
Norms/unable to work 1.120 1.109 1.103 1.1
MOS/unable to work 1.105 1.078 1.071 1.0
MOS/loss of work ability 1.052 1.052 1.040 1.0
BP, Bodily Pain; GH, General Health; MCS, Mental Component Summ
signiﬁcant; PCS, Physical Component Summary; PF, Physical Function
Survey; RE, Role Limitations due to Emotional Health; RP, Role Limitation
Health Survey; VT, Vitality.
* Values not explicitly stated were chosen to represent the largest subgrou
¼ 50 y, male, college education or more, married, one comorbid condit
†Outside the score range for the scale.married, and for persons with few or no comorbidities (Table 3).
Thus, for 50-year-olds, comparing PF scores of 49 and 50, the RR
for being unable to work due to health was 1.21 in the QM
Norms study and 1.15 in the MOS. Comparing PF scores of 19
and 20, the RRs were 1.05 in the QM Norms study and 1.01 in
the MOS.
These nonlinear effects are illustrated for the QM Norms
study in the third row of Figure 1, which shows, in particular
for the physical scales and for the PCS, a much stronger
association with inability to work for average score levels. The
last row of Figure 1 shows the absolute risks of being unable to
work for different score levels. For the PCS, the risk varies from
0.8% for persons scoring 50 to 38.6% for persons scoring 20.
For some scales, the RRs also varied signiﬁcantly by marital
status. The strongest associations between subscale score and
inability to work were found for married respondents (Table 3).
The estimated RRs for being unable to work due to health for
the subsamples with diabetes were fairly similar in the MOS andility to work, and loss of ability to work for a 1-point
VT SF RE MH PCS MCS
60 1.095 1.078 1.077 1.080 1.154 1.062
57 1.094 1.077 1.076 1.079 1.150 1.061
45 1.090 1.075 1.074 1.077 1.133 1.060
10 1.083 1.071 1.070 1.073 1.090 1.058
56 1.093 1.077 1.076 1.079 1.193 1.061
57 1.093 1.077 1.076 1.079 1.172 1.061
57 1.094 1.077 1.076 1.079 1.150 1.061
57 1.094 1.077 1.076 1.079 1.127 1.061
92 1.050 1.075 1.074 1.036 1.139 1.059
57 1.094 1.077 1.076 1.079 1.150 1.061
70 1.094 1.078 1.084 1.080 1.163 1.061
44 1.092 1.077 1.068 1.078 1.136 1.060
18 1.089 1.074 1.052 1.075 1.109 1.058
24 1.099 1.112 1.050 1.052 1.114 1.057
13 1.088 1.071 1.048 1.049 1.100 1.054
87 1.067 1.037 1.045 1.046 1.072 1.049
49 † 1.013 † 1.040 1.038 1.043
79 0.992 1.054 1.031 1.049 1.064 1.048
10 1.018 1.053 1.030 1.048 1.063 1.047
42 1.044 1.052 1.030 1.047 1.062 1.046
72 1.067 1.051 1.029 1.046 1.061 1.044
29 1.021 1.027 NS NS. 1.037 NS
00 1.069 1.073 1.058 1.056 1.099 1.055
99 1.084 1.095 1.041 1.043 1.096 1.046
69 1.068 1.049 1.028 1.045 1.060 1.043
ary; MH, Mental Health; MOS, Medical Outcomes Study; NS, not
ing; QM Norms, QualityMetric Patient-Reported Outcome Norming
s due to Physical Health; SF, Social Functioning; SF-36, Short-Form 36
p of patients with diabetes in the samples: base score level ¼ 40, age
ion.
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estimated RRs for a 1-point PF score difference were 1.12 in the
QM Norms sample and 1.11 in the MOS.
Finally, in the subgroup of the MOS that was able to work at
baseline, all scales were signiﬁcantly associated with loss of
ability to work at 6-month follow-up (Po 0.005). The associations
between score and loss of work ability were robust across
diseases, and no test of interaction between diagnosis and scale
score was signiﬁcant. Two scales, the GH and the VT, showed an
interaction with age so that the association between score
differences and loss of work ability was strongest among the
older age groups and very close to an RR of 1 for persons 30 to 40
years old. The estimated RRs for the subpopulations with dia-
betes ranged from 1.03 to 1.07.Conclusions
The current analyses aim to provide benchmarks for the inter-
pretation of SF-36 scores and to evaluate whether such bench-
marks are robust across disease and population subgroups. We
found no signiﬁcant differences across disease groups, but
signiﬁcant differences in RRs across important background var-
iables, particularly age, and by score level. These results suggest
that speciﬁc benchmarks for interpretation can be established for
a patient group on the basis of typical distribution of baseline
score, age, and other characteristics.
Some of our results raise new questions for research. For
example, the 1-point relative risk for mortality in the MHOS
varies by score level for most of the subscales but is constant for
the PCS. A possible reason may be that ﬂoor and ceiling effects
cause variations in relative risks for the SF-36 subscales. Floor
and ceiling effects are seen to a much lesser extent in the PCS.
The RRs presented for a 1-point score difference can be used
to calculate benchmarks for other score differences. For example,
we estimated that a 1-point lower score on the PF, GH, and PCS
implied a 9% increased risk of mortality for patients with DM. For
a 3-point score difference, a rough approximation of the
increased risk is 3  9 ¼ 27% and a closer approximation is the
RR (1.09) to the power of 3 ¼ 1.30.
The absolute magnitudes of the risks are important to bear
in mind. For example, in the MHOS study, the absolute risk of
mortality varied from 2.8% to 9.0% in the PF score range 50 to
20. For an absolute risk around 9%, an RR of 1.30 implies a risk
difference of 2.7%. For an absolute risk around 2.8%, the risk
difference for the same RR is 0.8%. For inability to work, the
relative risk was lower for low scores levels, where the
absolute risk was high. Part of the reason is that a constant
odds ratio is equivalent to a lower RR when the outcome is
frequent.
HRQOL research on benchmarks for interpretation has often
focused on the minimally important difference (MID). MIDs are
usually determined through a multifaceted approach including
patient ratings of importance of changes, as well as bench-
marks such as the ones included in this article. General
recommendations for MIDs for the SF-36 range from 2 to 4
points for different scales and score levels [5]. Yet, interpreta-
tion remains difﬁcult when an observed difference is statisti-
cally signiﬁcant and smaller than the MID [14]. In standard
medical decision making, the potential beneﬁt of a treatment is
weighted against the potential costs, such as economic costs,
risk of side effects, and so forth, yet the concept of MID
disregards the cost part of this equation. Thus, while MIDs are
useful as rough guidelines for determining sample size in
clinical studies [5,15], we hope that the presented benchmarks
for interpretation can enable a more nuanced discussion of the
interpretation of results.In DM research, small differences in SF-36 scores are common.
Differences in clinical variables [16] or various treatments pro-
duce small but statistically signiﬁcant SF-36 differences, espe-
cially for educational/behavioral interventions and some insulin
therapies [6].
The benchmarks discussed in the article should be interpreted
on a group level. For an individual, only score changes of 3 to 6
points can be reliably detected [5]. Any mean group change,
however, will reﬂect the balance of a range of individual
responses from clinically important deterioration, over stable
states, to clinically important improvement. Thus, similar to
medical indicators such as blood pressure, group differences
that are too small to be measured on an individual level (e.g., a
2 mm Hg difference) may have important public health conse-
quences [17].
The associations between score differences and work ability
were stronger for values of the background variables that are
normally associated with better health: younger age, married
status, fewer comorbid conditions, and higher SF-36 scores. Thus,
benchmarks such as work ability appear to be the most relevant
for the large proportion of patients with DM in relatively good
health. A possible reason is that people in poor health may have
developed coping strategies that allow them to work even in the
case of worsening of symptoms and function.
In the MOS mortality analyses, the associations were strongest
in the young age groups for the PF and GH scales and the PCS. In the
MHOS, the weakest associations were usually seen for participants
younger than 65 years. Medicare recipients, however, younger than
65 years constitute a special group with rather severe disabilities
that are likely to act as confounders in the analyses. Thus, the MOS
results regarding age seem the most trustworthy. Furthermore,
although the differences were small, associations in the MHOS were
strongest for persons with college education, married status, and
few comorbidities. This suggests that, similar to the results for work
ability, the association between SF-36 scores and mortality are
strongest for patients with DM who are not at high risk according to
other risk factors. Contrary to the results for work ability, however,
the associations were strongest for persons with low SF-36 scores,
suggesting that mortality is most useful as a benchmark for
patients with DM having SF-36 scores in the low range.
Our results agree with the results of numerous other studies
regarding the association between SF-36 scores and mortality
[18], hospitalization [19], and work ability [20]. Our observation
that the strength of these associations, however, may depend on
score level and background factors has so far received little
attention [15].
While we regard our analyses as helpful for interpretation
guidelines, their limitations should also be noted. We do not
claim that the associations necessarily reﬂect causal relation-
ships. In most instances, the associations will reﬂect a causal
effect of some disease process on mortality, hospitalization, or
work ability, but because the SF-36 scales do not measure speciﬁc
disease processes, a beneﬁcial effect of a treatment on SF-36
scores may reﬂect other disease processes than the ones respon-
sible for the associations examined in this article. Also, our
analyses have been limited by the available data, which focus
mainly on physical health rather than mental health. Studies on
additional relevant outcomes, such as overall medical expendi-
ture, sick days, and objective assessment of work productivity,
could offer additional important benchmarks for interpretation.
The three studies discussed in this article reﬂect different
samples that are not comparable; however, we regard this as a
strength of our study because it has allowed us to evaluate
robustness of results across samples. Finally, the presented RRs
do not take the statistical uncertainty into account. Thus, 10 of
the 457 RR estimates presented here were slightly less than 1
(varying from 0.979 to 0.996). We take these estimates as artifacts
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 9 9 3 – 1 0 0 01000of the overall modeling equations rather than evidence of truly
reduced risk of outcomes with lower SF-36 scores. While sample
sizes were generally large, some uncertainties were seen, in
particular in the parameter estimates from the MOS and QM
Norms studies. The satisfactory agreement between the two
studies regarding the results on work ability, however, provides
some support that the results are robust.
In conclusion, we estimate that for patients with diabetes, a 1-
point lower score on the PF and GH scales and the PCS was
associated with a 5% to 9% increased mortality risk. A 1-point
lower score on the PF, RP, BP, GH, VT, and SF scales and the PCS
implied a 2% to 4% increased risk of hospitalization in the next 6
months, a 7% to 12% increased risk of being unable to work, and a
4% to 7% increased risk of losing the ability to work over the next 6
months. We propose to use these results as benchmarks for the
interpretation of SF-36 results in studies of diabetes [16].Acknowledgments
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